shahajan baig
☆    

India,
2020-07-20 21:50
(14 d 14:37 ago)

Posting: # 21763
Views: 164
 

 USFDA guidance for petitioned ANDA [Regulatives / Guidelines]

Under the guidance of USFDA "Determining Whether to Submit an ANDA or a 505(b)(2) Application Guidance for Industry" it is mentioned as:

"A petitioned ANDA is a type of ANDA for a drug product that differs from the RLD in its dosage form, route of administration, strength, or active ingredient (in a product with more than one active ingredient) and for which FDA has determined, in response to a petition submitted under section 505(j)(2)(C) of the FD&C Act (suitability petition), that studies are not necessary to establish the safety and effectiveness of the proposed drug product. A petitioned ANDA is generally expected to provide the same therapeutic effect as the listed drug that was relied on as the basis of the suitability petition."

I want to know that how can suitability petition can be filed without establishing the safety and effectiveness of the proposed drug.

Thanks in advance

Regards,

Baig Shahajan

Regards,

SHAHAJAN BAIG
Activity
 Admin contact
20,964 posts in 4,373 threads, 1,460 registered users;
online 10 (1 registered, 9 guests [including 4 identified bots]).
Forum time: Tuesday 12:27 CEST (Europe/Vienna)

My doctor gave me six months to live,
but when I couldn’t pay the bill
he gave me six months more.    Walter Matthau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5